Skip to main content

Mayer Brown JSM and O’Melveny & Myers have advised on biomedical materials maker Shanghai Haohai Biological Technology Co’s $302 million IPO on the Hong Kong Stock Exchange.

At HK$59 per share, Shanghai Haohai priced its offering at the top of its range. The listing took place on April 30.

Shanghai Haohai will use the proceeds to pay for new production lines, production equipment and acquisitions, the company said.

Hong Kong partner Gigi Woo led the O’Melveny team that advised Shanghai Haohai, with support from Beijing partner Ke Geng.

Mayer Brown Hong Kong partners James Fong and Jason Elder represented UBS Securities as the sole sponsor, and UBS, CMB International Capital and CCB International Capital as the underwriters of the offering. 

Grandall Law Firm and Grandway Law Offices provided PRC legal advice to Shanghai Haohai and the underwriters, respectively.

Related Articles

2024 ALB China天达共和十五佳总法律顾问圆桌会议成功举办 (ZH/EN)

10月18日,2024 ALB天达共和十五佳总法律顾问圆桌会议在北京璞瑄酒店圆满举办。 本次盛会由天达共和律师事务所品牌运营总监刘思强女士主持,十五佳上榜总法及获奖代表出席了此次盛会。

功承瀛泰落子武汉,拓展华中布局(ZH/EN)

by Charlie Wu 吴卓言 |

总部位于上海的功承瀛泰律师事务所近日正式成立武汉办公室,成为该所在全国范围内的第16家分支机构。

报名开始:2025 ALB China 区域市场排名:环渤海地区 / 2025 ALB China Regional Ranking: Circum-Bohai Sea Area

ALB China 2025年首个区域市场榜单:2025 ALB China 区域市场排名:环渤海地区,现已接受提名。